PE20170938A1 - Suministro al sistema nervioso central de agentes terapeuticos - Google Patents
Suministro al sistema nervioso central de agentes terapeuticosInfo
- Publication number
- PE20170938A1 PE20170938A1 PE2017000503A PE2017000503A PE20170938A1 PE 20170938 A1 PE20170938 A1 PE 20170938A1 PE 2017000503 A PE2017000503 A PE 2017000503A PE 2017000503 A PE2017000503 A PE 2017000503A PE 20170938 A1 PE20170938 A1 PE 20170938A1
- Authority
- PE
- Peru
- Prior art keywords
- supply
- therapeutic agents
- nervous system
- central nervous
- sulfatase
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 102100022146 Arylsulfatase A Human genes 0.000 abstract 2
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108010089932 heparan sulfate sulfatase Proteins 0.000 abstract 2
- 230000002132 lysosomal effect Effects 0.000 abstract 2
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 abstract 1
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 abstract 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 abstract 1
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 abstract 1
- 102000005936 beta-Galactosidase Human genes 0.000 abstract 1
- 108010005774 beta-Galactosidase Proteins 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01046—Galactosylceramidase (3.2.1.46)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
Abstract
Se refiere a una composicion farmaceutica que comprende una enzima lisosomal a una concentracion de o mayor que 10mg/mL y un agente amortiguador, que comprende fosfato a una concentracion de hasta 50mM, donde la enzima lisosomal se selecciona de iduronato-2-sulfatasa recombinante (I2S), arilsulfatasa A (ASA), heparan N-sulfatasa (HNS), alfa-N-acetilglucosaminidasa (Naglu) y beta-galactosidasa (GLC). Dicha composicion es util en el tratamiento de trastornos de almacenamiento lisosomal
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35885710P | 2010-06-25 | 2010-06-25 | |
US36078610P | 2010-07-01 | 2010-07-01 | |
US38786210P | 2010-09-29 | 2010-09-29 | |
US201161435710P | 2011-01-24 | 2011-01-24 | |
US201161442115P | 2011-02-11 | 2011-02-11 | |
US201161476210P | 2011-04-15 | 2011-04-15 | |
US201161495268P | 2011-06-09 | 2011-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170938A1 true PE20170938A1 (es) | 2017-07-13 |
Family
ID=45352777
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000183A PE20180801A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa |
PE2012002498A PE20130648A1 (es) | 2010-06-25 | 2011-06-25 | Tratamiento del sindrome de sanfilippo tipo b |
PE2012002475A PE20130579A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa |
PE2012002474A PE20130578A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa |
PE2017001612A PE20180130A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
PE2012002476A PE20130589A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
PE2017000503A PE20170938A1 (es) | 2010-06-25 | 2011-06-25 | Suministro al sistema nervioso central de agentes terapeuticos |
PE2012002479A PE20130637A1 (es) | 2010-06-25 | 2011-06-25 | Suministro al sistema nervioso central de agentes terapeuticos |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000183A PE20180801A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa |
PE2012002498A PE20130648A1 (es) | 2010-06-25 | 2011-06-25 | Tratamiento del sindrome de sanfilippo tipo b |
PE2012002475A PE20130579A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa |
PE2012002474A PE20130578A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa |
PE2017001612A PE20180130A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
PE2012002476A PE20130589A1 (es) | 2010-06-25 | 2011-06-25 | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012002479A PE20130637A1 (es) | 2010-06-25 | 2011-06-25 | Suministro al sistema nervioso central de agentes terapeuticos |
Country Status (24)
Country | Link |
---|---|
US (14) | US9814764B2 (es) |
JP (21) | JP6250616B2 (es) |
CN (4) | CN106139133B (es) |
AR (6) | AR082025A1 (es) |
BR (1) | BR112012033214B1 (es) |
CA (1) | CA3171308A1 (es) |
CL (7) | CL2012003654A1 (es) |
DK (3) | DK3626257T3 (es) |
ES (3) | ES2896060T3 (es) |
HK (2) | HK1214149A1 (es) |
HR (3) | HRP20211520T1 (es) |
HU (6) | HUE052944T2 (es) |
LT (3) | LT3626257T (es) |
MX (1) | MX354776B (es) |
NZ (2) | NZ702800A (es) |
PE (8) | PE20180801A1 (es) |
PL (1) | PL2588130T3 (es) |
PT (6) | PT3103469T (es) |
RS (3) | RS62620B1 (es) |
RU (1) | RU2761342C2 (es) |
SI (3) | SI3626257T1 (es) |
SM (1) | SMT201600385B (es) |
TW (8) | TWI790444B (es) |
UA (2) | UA125743C2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
US20220133863A1 (en) * | 2010-06-25 | 2022-05-05 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
US9770410B2 (en) | 2010-06-25 | 2017-09-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of arylsulfatase A |
KR20240068752A (ko) | 2010-06-25 | 2024-05-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | 치료제들의 cns 전달 |
ES2896060T3 (es) | 2010-06-25 | 2022-02-23 | Shire Human Genetic Therapies | Métodos y composiciones para la administración al SNC de arilsulfatasa A |
EP3711778B1 (en) | 2011-12-02 | 2024-05-08 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
ES2728447T3 (es) | 2011-12-23 | 2019-10-24 | Shire Human Genetic Therapies | Tratamiento del déficit cognitivo del síndrome de Hunter para la administración intratecal de iduronato-2-sulfatasa |
EP2793922B1 (en) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
KR20220119187A (ko) * | 2013-05-15 | 2022-08-26 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
DK3397270T3 (da) * | 2015-12-30 | 2024-05-06 | Green Cross Corp | Sammensætninger til anvendelse i behandlingen af hunters syndrom |
AU2017222620B2 (en) | 2016-02-24 | 2022-06-16 | Biomarin Pharmaceutical Inc. | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof |
IL305449A (en) | 2016-04-15 | 2023-10-01 | Univ Pennsylvania | Gene therapy for the treatment of type II mucositis |
TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
JP7417514B2 (ja) * | 2018-02-28 | 2024-01-18 | 生化学工業株式会社 | 包装体およびその製造方法 |
CN108534695A (zh) * | 2018-05-04 | 2018-09-14 | 无锡恩特卫自动化检测设备有限公司 | 一种基于机器视觉***的瓶塞漏酒检测方法及装置 |
JP2020002130A (ja) | 2018-06-25 | 2020-01-09 | Jcrファーマ株式会社 | 蛋白質含有水性液剤 |
JP7253770B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
JP7253771B2 (ja) * | 2019-01-18 | 2023-04-07 | 株式会社大一商会 | 遊技機 |
JP2023545707A (ja) | 2020-10-14 | 2023-10-31 | デナリ セラピューティクス インコーポレイテッド | スルホグルコサミンスルホヒドロラーゼ酵素を含む融合タンパク質及びその方法 |
CN113283465B (zh) * | 2021-04-02 | 2022-04-29 | 电子科技大学 | 一种弥散张量成像数据分析方法及装置 |
CN115116623A (zh) * | 2022-06-28 | 2022-09-27 | 深圳市儿童医院 | 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133001A (en) * | 1959-11-26 | 1964-05-12 | Muset Pedro Puig | Stabilization of enzymes |
US4743265A (en) | 1986-04-23 | 1988-05-10 | Dij Catheter Corp | Articulated catheter placement device |
US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
EP0682524B1 (en) * | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5863782A (en) * | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
EP0900569B1 (en) | 1997-08-22 | 2002-10-02 | Seikagaku Corporation | Therapeutic agent for herniated intervertebral disc |
DK1137762T3 (da) * | 1998-12-07 | 2009-02-02 | Genzyme Corp | Behandling af Pompes sygdom |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US6368315B1 (en) | 1999-06-23 | 2002-04-09 | Durect Corporation | Composite drug delivery catheter |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
US20020099025A1 (en) * | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
US6866844B2 (en) * | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
WO2003032727A1 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
WO2003068159A2 (en) | 2002-02-11 | 2003-08-21 | Wake Forest University | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
WO2003090695A2 (en) * | 2002-04-25 | 2003-11-06 | Transkaryotic Therapies, Inc. | TREATMENT OF α-GALACTOSIDASE A DEFICIENCY |
CA2487815A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
EP1587923B1 (en) | 2003-01-22 | 2011-08-24 | Duke University | Improved constructs for expressing lysosomal polypeptides |
US20040180419A1 (en) | 2003-01-31 | 2004-09-16 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
JP5036302B2 (ja) | 2003-02-10 | 2012-09-26 | ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ | 炎症状態下に血液脳関門で示差的(differentially)に発現される核酸 |
CN1788017B (zh) * | 2003-02-10 | 2013-04-24 | to-BBB控股股份有限公司 | 炎症状态下在血脑屏障中差异表达的核酸 |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
CA2525236C (en) | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
NZ548871A (en) * | 2004-01-30 | 2009-06-26 | Shire Pharmaceuticals Ireland | Use of arylsulfatase A for treating metachromatic leukodystrophy |
US20060029656A1 (en) | 2004-02-03 | 2006-02-09 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
EP1720405A4 (en) | 2004-02-06 | 2008-08-27 | Biomarin Pharm Inc | MANUFACTURE OF HIGHLY PHOSPHORYLATED LYSOSOMAL ENZYMES AND USES THEREOF |
CN1922313B (zh) | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
JP2008516190A (ja) * | 2004-08-11 | 2008-05-15 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 酵素に基づく時間・温度インジケーター |
IL165334A0 (en) * | 2004-11-22 | 2006-01-15 | Mediwound Ltd | Debriding composition from bromelain and methods of producing same |
EP1889628B1 (en) * | 2005-05-11 | 2013-12-11 | JCR PHARMACEUTICALS Co., LTD. | Lipid liposome composition |
KR20080033242A (ko) | 2005-06-08 | 2008-04-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는cns 질환의 치료 방법 |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
DK1988823T3 (en) | 2006-02-09 | 2018-12-03 | Genzyme Corp | SLOW INTRAVENTRICULAR ADMINISTRATION |
CN101410408A (zh) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
BRPI0709737A2 (pt) | 2006-04-04 | 2011-07-26 | Zymenex As | processo para concentraÇço de um polipeptÍdeo |
GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
US8419710B2 (en) * | 2006-12-06 | 2013-04-16 | Medtronic, Inc. | Methods for infusing fluids via an implantable infusion system |
WO2008109677A2 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
WO2009017005A1 (ja) | 2007-07-27 | 2009-02-05 | Sharp Kabushiki Kaisha | 移動局装置、基地局装置、通信システム及びプログラム |
AU2008287340A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
EP2223934B1 (en) * | 2007-11-14 | 2012-10-03 | Institute Of Microbiology, Chinese Academy Of Sciences | Polypeptides for inhibiting influenza virus infection |
CA2904458C (en) | 2007-11-30 | 2017-07-25 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
WO2009131698A2 (en) | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
EP3778652A1 (en) | 2008-05-07 | 2021-02-17 | BioMarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
US8436489B2 (en) | 2009-06-29 | 2013-05-07 | Lightsail Energy, Inc. | Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange |
US9770410B2 (en) | 2010-06-25 | 2017-09-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of arylsulfatase A |
KR20240068752A (ko) * | 2010-06-25 | 2024-05-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | 치료제들의 cns 전달 |
MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
ES2896060T3 (es) | 2010-06-25 | 2022-02-23 | Shire Human Genetic Therapies | Métodos y composiciones para la administración al SNC de arilsulfatasa A |
KR20230159646A (ko) * | 2010-06-25 | 2023-11-21 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
EP2585105B1 (en) | 2010-06-25 | 2017-08-09 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
EP2588132A4 (en) | 2010-06-25 | 2014-10-15 | Shire Human Genetic Therapies | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS |
JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
EP2793922B1 (en) * | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
-
2011
- 2011-06-25 ES ES19192508T patent/ES2896060T3/es active Active
- 2011-06-25 RS RS20211359A patent/RS62620B1/sr unknown
- 2011-06-25 HR HRP20211520TT patent/HRP20211520T1/hr unknown
- 2011-06-25 RU RU2017125281A patent/RU2761342C2/ru active
- 2011-06-25 HU HUE16179150A patent/HUE052944T2/hu unknown
- 2011-06-25 BR BR112012033214-7A patent/BR112012033214B1/pt active IP Right Grant
- 2011-06-25 CN CN201610569581.XA patent/CN106139133B/zh active Active
- 2011-06-25 HU HUE19192679A patent/HUE055963T2/hu unknown
- 2011-06-25 RS RS20211191A patent/RS62520B1/sr unknown
- 2011-06-25 PE PE2018000183A patent/PE20180801A1/es unknown
- 2011-06-25 CN CN201510512218.XA patent/CN105233277B/zh active Active
- 2011-06-25 PT PT161791504T patent/PT3103469T/pt unknown
- 2011-06-25 PT PT117990358T patent/PT2588130T/pt unknown
- 2011-06-25 LT LTEP19192508.0T patent/LT3626257T/lt unknown
- 2011-06-25 PE PE2012002498A patent/PE20130648A1/es not_active Application Discontinuation
- 2011-06-25 DK DK19192508.0T patent/DK3626257T3/da active
- 2011-06-25 PT PT191925080T patent/PT3626257T/pt unknown
- 2011-06-25 DK DK16179150.4T patent/DK3103469T3/da active
- 2011-06-25 SI SI201132014T patent/SI3626257T1/sl unknown
- 2011-06-25 CN CN201510172262.0A patent/CN104857504A/zh active Pending
- 2011-06-25 NZ NZ702800A patent/NZ702800A/en not_active IP Right Cessation
- 2011-06-25 HR HRP20211660TT patent/HRP20211660T1/hr unknown
- 2011-06-25 LT LTEP16179150.4T patent/LT3103469T/lt unknown
- 2011-06-25 PE PE2012002475A patent/PE20130579A1/es active IP Right Grant
- 2011-06-25 HU HUE11799036A patent/HUE046856T2/hu unknown
- 2011-06-25 PT PT117990366T patent/PT2593131T/pt unknown
- 2011-06-25 HU HUE11799037A patent/HUE046409T2/hu unknown
- 2011-06-25 LT LTEP19192679.9T patent/LT3626258T/lt unknown
- 2011-06-25 ES ES16179150T patent/ES2858726T3/es active Active
- 2011-06-25 MX MX2013000321A patent/MX354776B/es active IP Right Grant
- 2011-06-25 SI SI201132007T patent/SI3626258T1/sl unknown
- 2011-06-25 PT PT117990374T patent/PT2585104T/pt unknown
- 2011-06-25 UA UAA201507529A patent/UA125743C2/uk unknown
- 2011-06-25 PE PE2012002474A patent/PE20130578A1/es not_active Application Discontinuation
- 2011-06-25 NZ NZ702803A patent/NZ702803A/en unknown
- 2011-06-25 RS RS20210291A patent/RS61683B1/sr unknown
- 2011-06-25 PT PT191926799T patent/PT3626258T/pt unknown
- 2011-06-25 HU HUE11799035A patent/HUE031036T2/en unknown
- 2011-06-25 UA UAA201507719A patent/UA125060C2/uk unknown
- 2011-06-25 CN CN201610086722.2A patent/CN105664142A/zh active Pending
- 2011-06-25 HU HUE19192508A patent/HUE056884T2/hu unknown
- 2011-06-25 SI SI201131959T patent/SI3103469T1/sl unknown
- 2011-06-25 PL PL11799035T patent/PL2588130T3/pl unknown
- 2011-06-25 PE PE2017001612A patent/PE20180130A1/es unknown
- 2011-06-25 DK DK19192679.9T patent/DK3626258T3/da active
- 2011-06-25 PE PE2012002476A patent/PE20130589A1/es not_active Application Discontinuation
- 2011-06-25 ES ES19192679T patent/ES2895655T3/es active Active
- 2011-06-25 CA CA3171308A patent/CA3171308A1/en active Pending
- 2011-06-25 PE PE2017000503A patent/PE20170938A1/es unknown
- 2011-06-25 PE PE2012002479A patent/PE20130637A1/es not_active Application Discontinuation
- 2011-06-27 AR ARP110102246A patent/AR082025A1/es not_active Application Discontinuation
- 2011-06-27 TW TW109118555A patent/TWI790444B/zh active
- 2011-06-27 AR ARP110102241A patent/AR081677A1/es not_active Application Discontinuation
- 2011-06-27 TW TW105115109A patent/TW201701899A/zh unknown
- 2011-06-27 TW TW112102995A patent/TW202337489A/zh unknown
- 2011-06-27 TW TW100122534A patent/TWI602573B/zh active
- 2011-06-27 TW TW106108970A patent/TWI609694B/zh active
- 2011-06-27 TW TW106127273A patent/TWI698252B/zh active
- 2011-06-27 TW TW106135183A patent/TWI669128B/zh active
- 2011-06-27 AR ARP110102242A patent/AR081678A1/es not_active Application Discontinuation
- 2011-06-27 TW TW100122529A patent/TW201212936A/zh unknown
- 2011-06-27 AR ARP110102243A patent/AR081679A1/es unknown
- 2011-06-27 AR ARP110102244A patent/AR081680A1/es unknown
- 2011-06-27 AR ARP110102245A patent/AR081681A1/es unknown
-
2012
- 2012-12-21 CL CL2012003654A patent/CL2012003654A1/es unknown
- 2012-12-21 CL CL2012003657A patent/CL2012003657A1/es unknown
- 2012-12-21 CL CL2012003656A patent/CL2012003656A1/es unknown
- 2012-12-21 CL CL2012003655A patent/CL2012003655A1/es unknown
-
2013
- 2013-05-10 US US13/892,076 patent/US9814764B2/en active Active
- 2013-08-23 US US13/974,457 patent/US9220677B2/en active Active
-
2015
- 2015-11-11 US US14/938,824 patent/US20160158324A1/en not_active Abandoned
- 2015-12-03 JP JP2015236539A patent/JP6250616B2/ja active Active
- 2015-12-17 JP JP2015246589A patent/JP2016094451A/ja active Pending
- 2015-12-17 JP JP2015246244A patent/JP6285409B2/ja active Active
- 2015-12-17 JP JP2015246258A patent/JP2016040335A/ja not_active Withdrawn
- 2015-12-18 JP JP2015246952A patent/JP6346162B2/ja active Active
-
2016
- 2016-02-04 US US15/016,141 patent/US10456454B2/en active Active
- 2016-02-25 HK HK16102145.2A patent/HK1214149A1/zh unknown
- 2016-03-22 US US15/077,046 patent/US20170042977A1/en not_active Abandoned
- 2016-06-13 HK HK16106769.8A patent/HK1218719A1/zh unknown
- 2016-10-27 SM SM201600385T patent/SMT201600385B/it unknown
- 2016-12-07 CL CL2016003159A patent/CL2016003159A1/es unknown
-
2017
- 2017-08-23 US US15/684,568 patent/US10646554B2/en active Active
- 2017-09-15 JP JP2017177784A patent/JP6466538B2/ja active Active
- 2017-09-26 US US15/715,748 patent/US11065307B2/en active Active
- 2017-10-03 CL CL2017002488A patent/CL2017002488A1/es unknown
- 2017-10-04 JP JP2017194508A patent/JP6522073B2/ja active Active
- 2017-10-04 JP JP2017194348A patent/JP6522072B2/ja active Active
-
2018
- 2018-07-16 US US16/036,584 patent/US11065308B2/en active Active
- 2018-10-11 JP JP2018192589A patent/JP6797876B2/ja active Active
- 2018-12-03 JP JP2018226358A patent/JP6898909B2/ja active Active
- 2018-12-04 JP JP2018227369A patent/JP6938456B2/ja active Active
-
2019
- 2019-07-18 US US16/515,568 patent/US11260112B2/en active Active
- 2019-09-17 US US16/573,557 patent/US11471516B2/en active Active
-
2020
- 2020-01-07 JP JP2020000930A patent/JP2020079244A/ja not_active Withdrawn
- 2020-02-14 JP JP2020023620A patent/JP2020079297A/ja active Pending
- 2020-02-17 JP JP2020024183A patent/JP2020079298A/ja active Pending
- 2020-02-26 CL CL2020000468A patent/CL2020000468A1/es unknown
- 2020-03-24 US US16/828,731 patent/US20200405825A1/en active Pending
-
2021
- 2021-02-23 HR HRP20210298TT patent/HRP20210298T1/hr unknown
- 2021-06-17 US US17/350,860 patent/US20220133862A1/en active Pending
- 2021-07-13 JP JP2021115564A patent/JP7087175B2/ja active Active
- 2021-07-13 JP JP2021115560A patent/JP7448507B2/ja active Active
- 2021-08-18 JP JP2021133184A patent/JP2021181489A/ja active Pending
- 2021-12-03 JP JP2021196898A patent/JP7359827B2/ja active Active
-
2022
- 2022-01-18 US US17/578,119 patent/US20230026836A1/en active Pending
- 2022-08-16 US US17/820,155 patent/US20230165942A1/en active Pending
-
2023
- 2023-02-02 JP JP2023014814A patent/JP2023052868A/ja active Pending
- 2023-02-20 JP JP2023024170A patent/JP2023062114A/ja active Pending
- 2023-05-11 JP JP2023078673A patent/JP2023099216A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170938A1 (es) | Suministro al sistema nervioso central de agentes terapeuticos | |
ES2650689T3 (es) | Administración de agentes terapéuticos al sistema nervioso central | |
PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
CO2019014682A2 (es) | Composiciones y métodos para enzimas de internalización | |
CY1122282T1 (el) | Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α | |
ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
NZ623123A (en) | A process for concentration of a polypeptide | |
PE20171798A1 (es) | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada | |
BR112013023774A2 (pt) | inibidores de glicosilceramida sintase | |
MX2010007846A (es) | Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas. | |
MX361668B (es) | Formulación de anticuerpos. | |
ZA201000149B (en) | Glp-1-fc fusion protein formulation | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
IN2012DN02471A (es) | ||
MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
CO6710913A2 (es) | Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes | |
MX2017001898A (es) | Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales. | |
EP1988915A4 (en) | METHOD FOR MODULATING CELLULAR ACTIVITY AND AGENTS FOR USE THEREFROM | |
CL2011000614A1 (es) | Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras. | |
UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
AR124100A2 (es) | Composiciones farmacéuticas para la administración intratecal de enzimas lisosómicas |